<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84066">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02027649</url>
  </required_header>
  <id_info>
    <org_study_id>K14 in bladder cancer</org_study_id>
    <secondary_id>CIR2013</secondary_id>
    <nct_id>NCT02027649</nct_id>
  </id_info>
  <brief_title>Detection of K14 in Bladder Cancer With a Non Invasive Technique</brief_title>
  <official_title>K14 in Urothelial Cells as a Pronostic and Diagnostic Marker in Bladder Cancer Patients Using a Non Invasive Technique.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      By an invasive technique keratin 14 has been identified as a prognostic factor in bladder
      cancer. This study aims to analyze whether through a non-invasive technique keratin 14 can
      be used as a diagnostic and prognostic marker for this cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Keratin 14</measure>
    <time_frame>At the time of study entry</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Bladder cancer</arm_group_label>
    <description>Patients who suffered a bladder cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients with urologic diseases of non tumoral origin</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital patients.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bladder cancer

        Exclusion Criteria:

          -  Inability to sign the informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Corporació Sanitària i Universitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Juan Francisco Delgado de la Poza, Medical Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 3, 2014</lastchanged_date>
  <firstreceived_date>January 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Juan Francisco Delgado de la Poza</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Bladder cancer</keyword>
  <keyword>Keratin 14</keyword>
  <keyword>Pronostic marker</keyword>
  <keyword>Diagnostic marker</keyword>
  <keyword>Noninvasive technique</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
